The beyond-use date (BUD) on your dog's compounded medication is the pharmacy's cutoff for using that preparation. It runs from compounding, rather than pickup or first opening, and assumes the stated storage conditions. Follow the assigned date; do not extend it because medicine remains or the bottle looks normal. If a dose is due and the date has passed, contact the prescribing clinic promptly for a replacement or other instructions. A missing date, unclear storage line, or changed appearance also needs clarification before you rely on that bottle.

This guide concerns compounded medication for companion dogs in the United States. The storage and dating concepts also explain many other pet prescriptions, but a preparation prescribed for one animal should not be used for another without veterinary direction. The oral and topical nonsterile date table below does not apply to sterile eye preparations or injections.

Beyond-use date versus manufacturer expiration date

A manufacturer expiration date and a compounded BUD serve a similar practical purpose: they set a limit for using a medicine under specified conditions. Their evidence and oversight differ. FDA-approved brand-name and generic drugs undergo review of safety, effectiveness, and quality. A finished compounded preparation does not acquire FDA approval merely because an approved tablet was used to make it. FDA's owner guidance explains this distinction and recommends asking whether a suitable approved animal or human drug could be used instead.

Compounding can meet a need such as a different strength, a liquid instead of a tablet, or removal of an unsuitable ingredient. Those changes also create a different formulation. The expiration date on the starting tablet bottle cannot simply answer how long the resulting flavored liquid will remain suitable. The veterinarian decides whether compounding is appropriate, and the compounder assigns the preparation's dating and storage instructions.

USP's BUD fact sheet explains that dating begins with compounding and considers degradation, microbial risks, and packaging. That fact sheet describes a 2019 revision and is useful for the concept, rather than as the current date table. In practice, use the calendar cutoff supplied with your prescription. If a sticker only says 'use within 14 days,' ask which starting date it refers to and request an unambiguous discard date. Do not calculate a new date from delivery.

For example, a bottle arriving several days after it was compounded has already used part of its assigned dating period. An unopened bottle does not receive a fresh period when you finally open it. Missed doses also do not add days to the label. Keep the package and delivery details if the usable time remaining seems shorter than expected; the pharmacy can resolve that issue with the prescriber.

The USP <795> default table: what the dates explain

The revised USP <795> nonsterile compounding chapter became official November 1, 2023, as NABP describes. The following limits are reproduced in a 2025 presentation authored by a USP compounding scientist and apply when there is no relevant USP-NF compounded-preparation monograph or preparation-specific stability information. They are maximum defaults, not promised shelf lives or instructions to change your bottle's date.

The pharmacist identifies the category. Capsules, liquids, treats, and gels cannot be classified reliably by appearance or flavor. Follow your preparation's storage label; the options in this table do not give you permission to switch temperatures. Physical or chemical instability can require a shorter date.

This is an explanation to bring to the pharmacy, not a home dating calculator. A bottle labeled for 30 days might have a shorter assigned date for reasons specific to its ingredients, formulation, or packaging. Conversely, seeing a longer date on a different formulation is a reason to ask about its basis, rather than evidence that either pharmacy is wrong. Compare the entire label and ask the compounder to explain the difference.

Why water activity and preservation matter

Water activity describes how much water is available in a preparation, rather than simply how wet it looks. USP uses it to help assess susceptibility to microbial growth. Formulation and preservation therefore matter alongside the active drug. A flavor name does not identify the vehicle, prove that a preservative is present, or establish a usable lifetime.

A useful question is: 'What information about this formulation supports the date on my label?' If the answer concerns water activity or preservation, ask the pharmacist to explain what that means for storage at home. You do not need to identify preservatives yourself or request a recipe. You need clear directions for this dispensed preparation, including any instruction to shake before measuring a dose.

Two versions of the same active drug may use different vehicles, concentrations, or packaging. Treat each refill as a prescription with its own instructions, particularly after a formulation change. Do not transfer an old bottle's date or storage rule onto a new one, and do not combine leftovers with a refill. Keeping them separately labeled avoids losing the connection between each preparation and its assigned cutoff.

When a pharmacy can support a different date

The USP-authored presentation describes extending a BUD with valid preparation-specific stability information, using a stability-indicating method relevant to the formulation and container material, up to 180 days through that pathway. Aqueous extensions also require antimicrobial effectiveness testing. A USP-NF monograph has its own specified limit. Components with an earlier expiration or BUD can shorten the final date. These conditions do not support a blanket claim that every compounded preparation can last six months.

Ask whether the date comes from a default, a monograph, or preparation-specific evidence, and whether the evidence fits the dispensed formulation, packaging, and storage conditions. A general statement that a pharmacy 'tests its products' leaves that question unanswered. The dispensing pharmacist can provide the practical explanation; the veterinarian can discuss whether the formulation remains the right choice for your dog.

An owner's observation that a bottle still smells normal cannot replace that evidence. Nor can an owner add preservatives, refrigerate a preparation to extend its date, or use a larger dose to compensate for suspected potency loss. Those actions would change the preparation or treatment without establishing that it remains suitable. When a date seems incompatible with the prescribed course, ask the clinic and pharmacy to resolve the supply plan together.

Check the label before the first dose

21 CFR 530.12 specifies labeling information for drugs dispensed for extralabel veterinary use, including identities, active ingredients, directions, and cautions. It does not itself provide a universal compounded BUD or storage rule. The checklist combines those federal labeling elements with practical questions about a compounded prescription; additional pharmacy requirements depend on applicable state rules.

The AVMA owner FAQ advises checking dog compounds for xylitol and contacting the veterinarian immediately if the medication's color, odor, or consistency changes. It also cautions against sharing a pet's compound without specific veterinary direction. A familiar drug name does not make another animal's concentration or directions suitable for your dog.

If a sticker and accompanying instructions conflict, keep both and contact the dispensing pharmacy. Describe the disagreement exactly instead of selecting whichever instruction is more convenient. Ask for corrected written instructions so everyone giving doses has the same information. A photograph of the intact label is useful for that conversation, but it should not become a substitute for keeping the original container.

Storage at home and after a temperature excursion

The published USP <659> storage bulletin defines a refrigerator as 2–8°C (36–46°F) and controlled room temperature as 20–25°C (68–77°F). It describes excursions under controlled conditions; that is not a general assurance that your particular compound tolerates a warm car or a power outage. 'Room temperature' and 'controlled room temperature' are not identical terms in that bulletin. Ask the pharmacy to clarify vague wording.

Choose a location that meets the label and prevents access by children or pets. Keep the preparation in its dispensing container unless the pharmacist gives different instructions. The package, closure, and any light protection are part of how the preparation is supplied. Before using a pill organizer or decanting a liquid for travel, ask whether the pharmacy can support that arrangement and for how long.

For a refrigerated prescription, ask about transport before pickup or shipment. Request a plan that maintains the required temperature without freezing the preparation. For a room-temperature prescription, avoid an unmonitored hot car, direct sunlight, or a location beside a heat source. These are practical ways to follow the label, rather than extra days of usable life.

If the medicine was left out, arrived warm, froze unexpectedly, or was exposed during a power failure, contact the pharmacy with the drug name, concentration, prescription number, assigned BUD, estimated temperature, and duration. Be clear about what you measured and what you are estimating. The response must depend on the preparation and the exposure; there is no universal number of safe hours for compounded dog medicine.

Returning the bottle to the prescribed temperature does not establish that it is still suitable or reset the date. If the next dose is approaching, involve the prescribing clinic so the storage question and the treatment plan are handled together. Keep a note of who provided the instructions and whether replacement was advised. Do not try to resolve an uncertain exposure by changing the dose.

What the potency evidence does and does not show

Burton and colleagues studied compounded chlorambucil, melphalan, and cyclophosphamide capsules in Veterinary and Comparative Oncology in 2017. Four pharmacies supplied each of the first two drugs and five supplied cyclophosphamide. Testing occurred on receipt and six weeks later, before the labeled BUDs. Across both time points, chlorambucil potency ranged from 71–104% and melphalan from 58–109% of labeled strength. The 58% result was at six weeks. All cyclophosphamide samples stayed within 10% of labeled strength at both measurements. Storage instructions varied or were absent.

This small, older study establishes variability in those tested chemotherapy capsules; it cannot estimate the chance that your dog's current liquid is subpotent. It also shows why a BUD alone is not a potency guarantee. The finding that cyclophosphamide samples met the study's comparison range matters: these results do not establish universal failure across compounded drugs or pharmacies.

For an owner, the practical response is to raise concerns about unexpected effects or lack of effect with the veterinarian, rather than diagnose the bottle. Keep its label, pharmacy details, storage history, and timing of doses available. A clinician can assess the dog and consider the preparation alongside other explanations. Do not increase a dose, switch suppliers, or substitute another formulation on the assumption that a percentage from this study applies to your prescription.

When the date passes: refills, disposal, and reporting

Plan refills around both the prescribed schedule and the BUD. A bottle may contain more doses than can be used before its cutoff. Ask the clinic and pharmacy how to arrange the next supply so that delivery time does not create a gap. If treatment changes or doses are missed, request a revised plan; leftover volume does not justify extending the assigned date.

If the date has already passed, do not give from that bottle. Contact the clinic promptly, especially when a dose is due, for replacement or other instructions appropriate to the prescription. Do not decide on your own to abandon treatment, double a later dose, or use another pet's medicine. This article cannot supply a universal missed-dose or interruption rule. The prescriber needs to address that decision for your dog.

FDA's disposal guidance prefers take-back collection or prepaid mail-back. If neither is readily available, flushing is appropriate only for medicines on the FDA flush list. Otherwise, where household disposal is appropriate, mix the medicine with an unappealing substance, seal it, and discard it as directed; do not crush pills. Remove personal information from empty packaging. Ask the pharmacist about drug-specific disposal, particularly for unusual dosage forms or hazardous medicines.

The University of Illinois veterinary guidance also favors take-back for unused or expired pet medicine. Confirm that a local collection program accepts what you have before making the trip. Controlled-drug status alone does not tell you whether to flush a particular compounded product. Keep leftovers inaccessible while arranging disposal; ask the dispensing pharmacy when the label or disposal instructions leave you uncertain.

For a suspected reaction or product defect, contact the veterinarian and compounder. Owners and veterinarians may also report problems using Form FDA 1932a through the instructions linked in FDA's owner guidance. Record what happened without asserting a cause you cannot establish. Ask whether to retain the container and remaining medicine for investigation before disposing of them, and keep them secured meanwhile.

Who oversees compounded animal drugs?

21 CFR 530.13 permits compounding from approved animal or human finished drugs under specified conditions, including professional oversight and state-law compliance. It does not authorize compounding from bulk drug substances. FDA's animal compounding overview and GFI #256 Q&A distinguish that finished-drug pathway from enforcement discretion for bulk compounding. Enforcement discretion does not make a compounded product FDA-approved.

FDA states that its animal-compounder inspections do not assess compliance with USP <795> or <797>; those chapters are not federally binding for animal compounding. Some states require them. FDA nevertheless addresses matters such as insanitary production. It also expresses stability concerns and encourages adverse-event reporting, although compounders lack the reporting requirements that apply to approved animal-drug sponsors. The distinction is FDA premarket review and federal requirements, rather than a claim that no regulator ever oversees a pharmacy.

As of this October 7, 2026 review, FDA's August 27 announcement describes draft GFI #256B for bulk compounding under current good manufacturing practice at federally registered facilities. Comments began August 28; FDA asks for comments by November 27 for consideration before further decisions. This remains a proposed enforcement policy. It does not extend the BUD on your bottle or approve a compounded medicine. For today's prescription, the practical decision remains the assigned date, its storage conditions, and clear instructions from the pharmacy and prescriber.

Sources

• USP: Beyond-Use Dates fact sheet (June 2019; historical conceptual background)

• USP-authored compounding presentation hosted by NCPA (November 2025; pages 12–15)

• 21 CFR 530.13: Compounding from approved animal and human drugs

• 21 CFR 530.12: Extralabel-use labeling

• FDA: GFI #256 questions and answers

• FDA: Animal Drug Compounding

• FDA: Approved versus pharmacy-compounded pet medicines

• FDA: Draft GFI #256B announcement (August 27, 2026)

• AVMA: Compounding FAQ for pet owners

• Burton et al.: Potency and stability of compounded chemotherapy capsules. Veterinary and Comparative Oncology (2017)

• USP <659>: Packaging and Storage Requirements (2017 revision bulletin)

• FDA: Disposal of Unused Medicines

• University of Illinois: Safe Disposal of Pet Medications (February 2026)

• NABP: Revised USP compounding chapters and pharmacy oversight